Table 2

Patient characteristics according to PVR levels at follow-up

VariablePVR ≤10 WU (n=62)PVR >10 WU (n=71)P value
Age (years)33 (25–48)33 (26–40)0.532
Female sex, n (%)44 (71)53 (75)0.634
WHO-FC (Ⅰ/Ⅱ/III/IV), n9/48/5/01/38/30/2<0.001
6-MWD (m)493±93411±95<0.001
BNP (pg/mL)15 (8–28)148 (41–320)<0.001
Mean RAP (mm Hg)3 (2–5)6 (4–8)<0.001
Mean PAWP (mm Hg)7 (5–9)6 (5–8)0.273
Mean PAP (mm Hg)35±1058±12<0.001
SvO2 (%)73±561±8<0.001
Cardiac index (L/min/m2)3.12 (2.56–3.85)1.95 (1.68–2.34)<0.001
SVI (mL/m)43.5 (36.8–49.4)25.2(20.6–32.3)<0.001
PVR (WU)5.7 (4.0–7.9)17.0 (13.2–21.6)<0.001
ERS/ESC risk score, n (%)<0.001
 Low risk54 (87)19 (27)
 Intermediate risk8 (13)49 (69)
 High risk0 (0)3 (4)
Medication
 ERA, n (%)44 (71)9 (13)<0.001
 PDE-5i, n (%)33 (53)7 (10)<0.001
 Riociguat, n (%)4 (7)0 (0)0.045
 Epoprostenol, n (%)27 (44)43 (61)0.05
 Epoprostenol dose (ng/kg/min)27 (23–31)15 (9–27)0.854
 Selexipag, n (%)1 (2)0 (0)0.466
 CCB, n (%)3 (5)3 (4)0.593
 Double therapy, n (%)5 (8)7 (10)0.719
 Triple therapy, n (%)33 (53)3 (4)<0.001
  • Values are presented as mean±SD, median (IQR) or n (%).

  • BNP, B-type natriuretic peptide; CCB, calcium channel blocker; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology; 6-MWD, 6 min walk distance; PAP, mean pulmonary artery pressure; PAWP, pulmonary arterial wedge pressure; PDE-5i, phosphodiesterase type five inhibitor; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SVI, stroke volume index; SvO2, mixed venous oxygen saturation; WHO-FC, WHO functional class; WU, Wood unit.